Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salmeterol/fluticasone fixed-combination versus separate inhalers in severe COPD
2007-003597-25Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salmeterol + fluticasone, salmeterol and Flixocort in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Frequency of exacerbations. Started Jul 2008; status: completed.
02
Drugs
salmeterol + fluticasonesalmeterolFlixocort
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-003597-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003597-25.